Navigation Links
Stroke drug kills bacteria that cause ulcers and tuberculosis
Date:12/20/2012

Bethesda, MDA drug currently being used to treat ischemic strokes may prove to be a significant advance in the treatment of tuberculosis and ulcers. In a new research report appearing online in The FASEB Journal, a compound called ebselen effectively inhibits the thioredoxin reductase system in a wide variety of bacteria, including Helicobacter pylori which causes gastric ulcers and Mycobacterium tuberculosis which causes tuberculosis. Thioredoxin and thioredoxin reductase proteins are essential for bacteria to make new DNA, and protect them against oxidative stress caused by the immune system. Targeting this system with ebselen, and others compounds like it, represents a new approach toward eradicating these bacteria.

"This new antibacterial principle provides better chances of surviving an infection," said Arne Holmgren, M.D., Ph.D., a researcher involved in the work from the Division of Biochemistry in the Department of Medical Biochemistry and Biophysics, at Karolinska Institutet in Stockholm, Sweden. "Since ebselen is also an antioxidant, the present mechanism can be described as a 'two for the price of one' antioxidant action in inflammation, and specific targeting of multi-resistant bacterial complications and sepsis."

Building on previous observations where ebselen has shown antibacterial properties against some bacteria, Holmgren and colleagues hypothesized that the bacteria sensitive to ebselen relied solely on thioredoxin and thioredoxin reductase for essential cellular processes. They investigated this by testing it on strains of E. coli with deletions in the genes for thioredoxin, thioredoxin reductase and the glutaredoxin system. They found that strains with deletions in the genes coding for glutaredoxin system were much more sensitive than normal bacteria. Researchers further tested ebselen against Helicobacter pylori and Mycobacterium tuberculosis, which both naturally lack the glutaredoxin system and are frequently resistant to many commonly used antibiotics, and found both to be sensitive to ebselen.

"As rapidly as these organisms evolve, we need new drugs sooner rather than later," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "The fact that these scientists have found a new target for killing some of the most resistant bacteria is great news, but the fact that we already have at least one drug which we could possibly use now makes the news even better."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related medicine news :

1. UGA research offers new targets for stroke treatments
2. US Drug Watchdog Now Urges Yaz Yasmin Birth Control Pill Users Who Suffered a Stroke, Blood Clots, or a Heart Attack to Call the Johnson Law Group for a Legal Review
3. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
4. Silent stroke can cause Parkinsons disease
5. Neurocritical Care & Stroke Conference slated for March 2013
6. Telestroke networks can be cost-effective for hospitals, good for patients
7. High Blood Pressure Poses Bigger Stroke Risk for Blacks, Study Says
8. Changes in the gut bacteria protect against stroke
9. Blau, Brown & Leonard, LLC Settlements Near Two Million Dollars on Behalf of Women who Endured DVT's, PE's and Strokes from Yaz, Yasmin and Ocella
10. Stress, Depression Linked to Raised Stroke Risk in Seniors
11. RSNA: New Study Finds Brain Angioplasty and Stents Safe and Effective for Stroke Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... HIMSS ... will keynote Day 2 of the HIMSS Healthcare Security Forum, the nation’s foremost ... Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will deliver his keynote, The ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: ... a major advancement in drug therapy for patients living with relapsing and primary ... a novel B cell targeted therapy that has been proven to significantly reduce ...
(Date:7/26/2017)... ... July 26, 2017 , ... A major challenge many labs ... freeze drying samples and a lengthy freeze dry cycle are a few common challenges ... drying techniques, as well as new accessories and advancements in laboratory freeze dryers that ...
(Date:7/26/2017)... ... July 26, 2017 , ... The ... Process Validation and Process Validation Statistics Conferences in Bethesda, Maryland, 12 – ... challenges faced by process validation professionals and statisticians today. , “These conferences ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Team Type ... access to medicine for everyone affected by diabetes, is excited to announce the 106 ... Global Ambassador Program. , Established in 2005, the Team Type 1 Foundation has ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
(Date:7/10/2017)... The Institute for In Vitro Sciences (IIVS), ... of a VITROCELL® inhalation exposure system thanks to a ... device, which is designed to replace animals in inhalation ... to airborne test materials in an environment that mimics ... for testing combustible tobacco products, as well as next ...
(Date:7/10/2017)...  The tenth annual BioPharm America™ will ... at the Sheraton Boston Hotel, September 26–27. The event ... decision makers and innovative biotech startup companies. The event ... two impactful days. BioPharm America is now part of ... opportunities with 4,500+ life science industry influencers participating in ...
Breaking Medicine Technology: